At the IGTP TODAY

News

- Innovation

The Caixaimpulse Programme selects a project from the Translational Endoscopy Group

An IGTP project is amongst the twenty selected this year for support by the Caixaimpulse Programme of the "la Caixa" Foundation and CaixaCapital Risc.   The project led by Dr Dr Lorenzo-Zúñiga and Dr Ramon Bartolí of the Translational Endoscopy Group, aims to enter into production of CoverGel, a topical hydrogel for use in therapeutic endoscopic operations to avoid heat damage to the intestinal mucosa.

The Comparative Medicine and Bioimage Centre of Catalonia (CMCiB) opens for business

In June this year the new Comparative Medicine and Bioimage Centre of Catalonia (CMCiB) started its normal working activities.  Located at the highest point of the campus, the CMCiB is a centre promoted by the Germans Trias i Pujol Research Institute (IGTP) and dedicated to biomedical research and training.  The centre is an important addition to scientific infrastructures in southern Europe and is the only one in Spain, it has been set up to become a reference in comparative medicine, bioimaging and computational models with a clear remit to promote alternative research models and methods

- Innovation

Aniling chosen for an intensive preparation program for Boston

The IGTP-PMPPC applied health technology spin-off is one of five selected by ACCIÓ in the first edition of 'Road to Boston'. Aniling is one of five applied health technology Catalan start-ups that has started an intensive six-month tailored program to prepare for entry to Boston, one of the principal hubs in this field, to establish first contacts with key players in the sector.  

- Innovation

Researchers at Can Ruti Campus enter into a licence agreement for the worldwide rights to the use of biomarker soluble neprilysin (sNEP) for assessing risk stratification and prognosis of heart failure patients

23 April 2016.  The group led by Dr Antoni Bayés-Genís of the Department of Cardiology of the Germans Trias i Pujol Hospital (HUGTiP) and the Germans Trias i Pujol Health Research Institute (IGTP) have signed a licence agreement with the American Company Critical Diagnostics for biomarker soluble neprilysin (sNEP).